Olumiant™ (baricitinib) tablets – A New Option in Rheumatoid Arthritis (RA)

<p>HEALTH CANADA HAS AUTHORIZED THE SALE OF THIS COVID-19 DRUG BASED ON LIMITED CLINICAL TESTING IN HUMANS AND/OR QUALITY INFORMATION</p><p>Bamlanivimab is indicated for:</p><p>The treatment of adults and pediatric patients 12 years of age or older with mild to moderate COVID-19 who weigh at least 40 kg and who are at high risk of progressing to severe COVID-19 illness and/or hospitalization.<br></p><p>The use of bamlanivimab is permitted under an interim authorization delivered in accordance with section 5 of the COVID-19 Interim order (IO)*, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization.&nbsp; The interim authorization is associated with Terms and Conditions that need to be met by the sponsor to ascertain the continued quality, safety and efficacy of the product. For further information on authorization under this pathway, please refer to Health Canada’s IO Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.</p><p>*<a target="_blank" rel="nofollow noopener noreferrer" href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/interim-order-import-sale-advertising-drugs.html#a2.8">https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccine...</a></p><div><br><br></div>